[A18-47] Ixekizumab (psoriatic arthritis) - Addendum to Commission A18-14
Last updated 16.08.2018
Project no.:
A18-47
Commission:
Commission awarded on 09.07.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Indication:
Patients with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more
Result of dossier assessment:
Now added benefit not proven for any of the three subindications
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-14 | Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-08-16 A G-BA decision was published.